

Express Mail Label No. EL 933049160 US
Attorney Docket No. 57109 (71699)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED
CENTRAL FAX CENTER**

APPLICANT(S)	S. Denmeade, et al.	EXAMINER:	S. Liu
U.S.S.N.:	09/627,600	GROUP:	1653
FILED (U.S.):	July 28, 2000	Conf. No.	3631
FOR:	ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)		

NOV 18 2003

OFFICIAL

BOX SEQUENCE
Commissioner for Patents
Washington, D.C. 20231

Sir/Madam:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

The following is in response to the Notice to Comply with Requirements for
Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence
Disclosures, mailed July 3, 2002, in the above-referenced application.

Enclosed herewith for filing in the subject application are the following:

1. Paper Copy of Sequence Listing previously submitted;
2. New Computer Readable Form (CRF) of Sequence Listing;
3. Copy of Notice To Comply With Requirements For Patent Applications
Containing Nucleotide Sequence And/Or Amino Acids Sequence Disclosures;
4. Copy of Error Report indicating unreadable disc;
5. Amendment directing entry of Paper Copy of Sequence Listing into specification
[included in this paper];
6. Statement Accompanying Submission Of Sequence Listing Under 37 C.F.R. §
1.821(g) (included in this paper);
7. Associate Power of Attorney; and
8. Change of Correspondence Address.

Attorney Docket No. 57109 (71699)
U.S.S.N. 09/627,600
Filed (U.S.): July 28, 2000
Page 2 of 2

AMENDMENT DIRECTING ENTRY OF SEQUENCE LISTING

At the last page of the specification, please enter the attached paper copy of the Sequence Listing (25 pages) and number the pages as appropriate.

STATEMENT ACCOMPANYING SUBMISSION OF SEQUENCE LISTING

Provided herewith is a Paper Copy of a Sequence Listing for the nucleotide and/or amino acid sequence(s) in this application. Each Sequence has been assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823. An amendment directing entry of the Paper Copy of the Sequence Listing into the specification is provided above.

Applicants further provide a Computer Readable Form (CRF) corresponding to the Paper Copy of the Sequence Listing provided herewith. Pursuant to 37 C.F.R. § 1.821(g), Applicants' agent hereby states that the CRF corresponds exactly to the Paper Copy of the Sequence Listing provided herewith. Applicants' agent further hereby states that the contents of the Paper Copy of the Sequence Listing and CRF do not go beyond the disclosure in the Application as filed and do not introduce new matter.

If for any reason, the fee paid is inadequate or credit is owed for any excess fee paid, you are hereby authorized and requested to charge Deposit Account No. 04-1105.

Date:

July 18, 2002

Respectfully submitted,

Dianne M. Rees
Dianne M. Rees, Ph.D.
(Reg. No. 45,281)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209

Telephone: 617-439-4444
Customer No. 21874
BOS2_307161.1

Mailing Date: 7/18/02

Attorney/Sec: Dymal/hurt

Client: 71699

Docket No.: 57109

Inventors: Denmeade, et al

Serial No.: 09/627,600

Patent No.:

Filing Date: 7/28/00

Grant Date:

The dating stamp of the Patent and Trademark Office hereon will be taken as the date of filing of:

Response to Notice of Missing Requirements;
copy of paper sequence & disk;
copy of previously filed response 10/19/01
Change of Address
Associate Power of Attorney

Due Date: 8/3/02

Attorney's Docket No.: 07265-191001 / DM-3575

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Isaacs et al. Art Unit : 1653
 Serial No. : 09/627,600 Examiner : H. Robinson
 Filed : July 28, 2000
 Title : ACTIVATION OF PEPTIDE PRODRUGS BY HK2

BOX SEQUENCE

Commissioner for Patents
 Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
 FOR PATENT APPLICATIONS CONTAINING
 NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated September 21, 2001 (copy enclosed), applicants submit herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicants submit an initial Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f).

Applicants respectfully request entry of the paper copy and computer readable copy of the Sequence Listing filed herewith for the instant application. Furthermore, applicants request entry of the following amendments.

In the specification:

Insert the paper copy of the Sequence Listing filed herewith following the Oath/Declaration.

Replace the paragraph beginning at page 4, line 10, with the following rewritten paragraph:

--Fig. 1 is a portion of the amino acid sequence of Semenogelin I (SEQ ID NOs:1-4) and Semenogelin II (SEQ ID NOs:5-11), showing the cleavage sites for human kallikrein 2.--

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

October 19, 2001
 Date of Deposit

Shabreen Mehjabeen
 Signature

SHABREEN MEHTABEEN
 Typed or Printed Name of Person Signing Certificate